{"contentid": 488525, "importid": NaN, "name": "Roivant merging with Montes Archimedes to go public in $7.3 billion SPAC deal", "introduction": "Switzerland-based biopharma Roivant Sciences and Montes Archimedes Acquisition, a special purpose acquisition company (SPAC) sponsored by Patient Square Capital, have entered into a definitive business combination agreement.", "content": "<p>Switzerland-based biopharma Roivant Sciences and Montes Archimedes Acquisition (Nasdaq: MAAC), a special purpose acquisition company sponsored by Patient Square Capital, have entered into a definitive business combination agreement.</p>\n<p>Upon closing of the transaction, outstanding shares and warrants of MAAC, shares of which were up 3.5% at $10.2 pre-market on Monday, will be exchanged for newly-issued shares and warrants of Roivant Sciences, which is expected to be listed on Nasdaq under the new ticker symbol &ldquo;ROIV.&rdquo;<br /> <br /> The transaction is expected to deliver up to $611 million of gross proceeds to fund discovery and development programs. This includes up to $411 million currently held in MAAC&rsquo;s trust account, as well as a concurrent $200 million common stock private investment in public equity (&ldquo;PIPE&rdquo;) priced at $10.00 per share. New institutional and strategic investors and existing Roivant shareholders have committed to participate in the PIPE.</p>\n<p>Jim Momtazee, managing partner of Patient Square Capital, will join Roivant&rsquo;s board of directors. Prior to founding Patient Square Capital, Mr Momtazee was a 21-year veteran of KKR where he helped form its health care investment team 20 years ago and ran that team for over a decade.<br /> <br /> &ldquo;Roivant is at the cutting edge of using technology to discover and develop transformative medicines for a wide range of serious diseases, and in a very short time they have established a remarkable track record of building subsidiaries that have run successful registrational clinical trials for approved medicines,&rdquo; said Mr Momtazee. <br /> <br /> Roivant will continue to operate under its current management team led by chief executive Matthew Gline. Roivant founder Vivek Ramaswamy will continue to serve as executive chairman.</p>\n<h2><strong>Apportion of shares</strong></h2>\n<p>Assuming no redemptions of MAAC shares, current shareholders of Roivant will own approximately 92% of Roivant immediately post-closing (including shares issued in connection with Roivant&rsquo;s recent acquisition of Silicon Therapeutics and existing Roivant shareholder participation in the PIPE).<br /> <br /> The closing of this transaction is expected in the third quarter of 2021 and is subject to the approval of MAAC&rsquo;s shareholders and the satisfaction or waiver of certain other customary closing conditions.</p>\n<p>In the fall of 2019, <a href=\"https://www.thepharmaletter.com/article/sumitomo-dainippon-and-roivant-confirm-strategic-alliance\">Roivant entered a deal with Japan&rsquo;s Sumitomo Dainippon Pharma</a> (TYO: 4506) to sell ownership of five of the Vant companies it had set up over several years for around $3 billion.&nbsp;</p>", "date": "2021-05-04 10:13:00", "meta_title": "Roivant merging with Montes Archimedes to go public in $7.3 billion SP", "meta_keywords": "Roivant Sciences, Montes Archimedes Acquisition, Merger, SPAC deal", "meta_description": "Roivant merging with Montes Archimedes to go public in $7.3 billion SPAC deal", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-03 15:47:41", "updated": "2021-05-04 10:14:14", "access": NaN, "url": "https://www.thepharmaletter.com/article/roivant-merging-with-montes-archimedes-to-go-public-in-7-3-billion-spav-deal", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "roivant_logo_big.jpg", "image2id": "roivant_logo_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": NaN, "topic_tag": "Companies, mergers and acquisitions, Management", "geography_tag": "Switzerland, USA", "company_tag": "Montes Archimedes Acquisition, Roivant Sciences", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-04 10:13:00"}